Nauck MA, Petrie JR, Sesti G et al (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
These rates increase to 64.1% and 84.4% respectively by the two-year mark
PLoS biology
veterans with type 2 diabetes and a pre-existing substance use disorder found that GLP-1 initiation was associated with roughly 40% lower risk of overdose compared to other diabetes medications
Glutathione isn't some exotic import
in: PubMed | Google Scholar 1 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ontario, Canada